Abbott Laboratories (Pakistan) Limited (ABOT) Financial Statements, Ratios & Dividends
About
Abbott Laboratories (Pakistan) Ltd. engages in the manufacture, import, and marketing of pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital, and consumer products. It operates through the following segments: Pharmaceutical, Nutritional, Diagnostics, and Others. The Pharmaceutical segment deals with the manufacture, import, and marketing of research based pharmaceutical products registered with the Drug Regulatory Authority of Pakistan. The Nutritional segment imports and markets pediatric nutritional products and medical nutritional products. The Diagnostics segment covers the import and marketing of diagnostic equipment, molecular devices, and testing kits. The Others segment represents the import and marketing of diabetes care products and manufacturing and marketing of general healthcare products. The company was founded on July 2, 1948 and is headquartered in Karachi, Pakistan.
Financial Highlights
| FY2025 | FY2024 | ||
|---|---|---|---|
| Revenue | 75.40B | 68.18B | |
| Gross Profit | 25.27B | 18.89B | |
| Net Income | 7.97B | 5.23B | |
| EPS | 81.37 | 53.46 | |
| ROE | 28.79% | 24.95% | |
| ROA | 18.64% | 13.95% | |
| Gross Margin | 33.51% | 27.71% | |
| Net Margin | 10.57% | 7.68% | |
| Current Ratio | 2.32 | 1.99 | |
| DPS | 40.00 | 10.00 | |
| Free Cash Flow | 7.97B | 2.11B |
| FY2025 | FY2024 | ||
|---|---|---|---|
| Total Revenue | 75.40B | 68.18B | |
| Cost of Goods Sold | -50.13B | -49.29B | |
| Gross Profit | 25.27B | 18.89B | |
| SG&A Expenses | -12.34B | -10.26B | |
| Research & Development | -136.36M | -81.06M | |
| Depreciation | -1.89B | -1.77B | |
| Other Operating Expense | -300.03M | -278.04M | |
| Total Operating Expense | -62.77B | -59.82B | |
| Operating Income (EBIT) | 12.62B | 8.35B | |
| Interest Income | 546.00M | 464.36M | |
| Interest Expense | -75.66M | -23.61M | |
| Equity in Earnings | 0 | 0 | |
| Other Non-Operating Income | 126.65M | 227.44M | |
| Total Non-Operating Income | 875.88M | 668.18M | |
| Pre-Tax Income | 13.50B | 9.02B | |
| Income Tax | -5.53B | -3.79B | |
| Minority Interest | 0 | 0 | |
| Net Income | 7.97B | 5.23B | |
| EBITDA | 14.51B | 10.13B | |
| EPS (Basic) | 81.37 | 53.46 | |
| EPS (Diluted) | 81.37 | 53.46 | |
| Gross Margin | 33.51% | 27.71% | |
| Operating Margin | 16.74% | 12.25% | |
| EBITDA Margin | 19.25% | 14.86% | |
| Pre-Tax Margin | 17.90% | 13.23% | |
| Net Margin | 10.57% | 7.68% |
| FY2025 | FY2024 | ||
|---|---|---|---|
| Profitability | |||
| Return on Equity (ROE) | 28.79% | 24.95% | |
| Return on Assets (ROA) | 18.64% | 13.95% | |
| Return on Invested Capital | 28.60% | 24.90% | |
| Gross Margin | 33.51% | 27.71% | |
| Operating Margin | 16.74% | 12.25% | |
| EBITDA Margin | 19.25% | 14.86% | |
| Net Margin | 10.57% | 7.68% | |
| Pre-Tax Margin | 17.90% | 13.23% | |
| Liquidity | |||
| Current Ratio | 2.32 | 1.99 | |
| Quick Ratio | 1.32 | 0.95 | |
| Leverage | |||
| Debt / Equity | 0.02 | 0.00 | |
| Debt / Assets | 0.01 | 0.00 | |
| LT Debt / Equity | 0.01 | 0.00 | |
| LT Debt / Assets | 0.01 | 0.00 | |
| Net Debt | -12.85B | -6.13B | |
| Total Debt | 487.98M | 52.23M | |
| Efficiency | |||
| Asset Turnover | 1.76 | 1.82 | |
| Inventory Turnover | 3.94 | 3.81 | |
| Per Share | |||
| Book Value Per Share | 323.04 | 242.33 | |
| Tangible Book Per Share | 323.03 | 242.32 | |
| Cash Per Share | 136.24 | 63.15 | |
| Total Debt Per Share | 4.98 | 0.53 | |
| Working Capital Per Share | 179.95 | 118.50 | |
| Shares & Market | |||
| Total Shares Outstanding | 97,900,302 | 97,900,302 | |
| Market Cap | 102.81B | 121.19B | |
| Enterprise Value | 89.96B | 115.06B | |
| Employees | 1,380 | 1,406 | |
| Shareholders | 3,988 | 3,988 | |
| FY2025 | FY2024 | ||
|---|---|---|---|
| Dividends Per Share | 40.00 | 10.00 | |
| Dividend Yield | 3.81% | 0.81% | |
| Payout Ratio | 49.16% | 18.70% | |
| Total Dividends Paid | -971.56M | -1.03B |
| FY2025 | FY2024 | ||
|---|---|---|---|
| P/E Ratio | 12.91 | 23.15 | |
| P/B Ratio | 3.25 | 5.11 | |
| P/S Ratio | 1.36 | 1.78 | |
| P/CF Ratio | 9.13 | 23.60 | |
| EV/EBITDA | 6.20 | 11.35 | |
| Market Cap | 102.81B | 121.19B | |
| Enterprise Value | 89.96B | 115.06B |
| TTM | ||
|---|---|---|
| Income | ||
| Revenue | 77.02B | |
| Gross Profit | 27.44B | |
| Operating Income | 13.42B | |
| Net Income | 8.56B | |
| EBIT | 13.42B | |
| Free Cash Flow | 6.32B | |
| EPS (Basic) | 87.47 | |
| Margins | ||
| Gross Margin | 35.63% | |
| Operating Margin | 17.43% | |
| Net Margin | 11.12% | |
| Returns | ||
| Return on Equity (ROE) | 29.26% | |
| ROIC | 0.29% | |
| Coverage & Debt | ||
| Interest Coverage | 182.4x | |
| Dividend Coverage | 2.94 | |
| Debt / Revenue | 0.01 | |
| Valuation & Scores | ||
| P/E (TTM) | 10.57 | |
| Sloan Ratio | 4.26 | |
| Zmijewski Score | -3.18 | |
Computed Metrics (Latest Period)
| FY2025 | ||
|---|---|---|
| Extended Returns | ||
| Return on Common Equity | 28.79% | |
| Return on Tangible Equity | 28.79% | |
| Return on Tangible Assets | 18.64% | |
| Return on Total Capital | 45.17% | |
| ROCE | 41.78% | |
| Growth | ||
| EPS Diluted Growth | 0.52% | |
| Sustainable Growth Rate | 14.64% | |
| Quality & Risk Scores | ||
| Piotroski F-Score | 7 | |
| Zmijewski Score | -3.19 | |
| Sloan Ratio | -0.59 | |
| Valuation (Computed) | ||
| Graham Number | 769.06 | |
| Tobin's Q Ratio | 2.16 | |
| Leverage & Coverage | ||
| Interest Coverage | 166.8x | |
| Total Debt / Capital | 0.02% | |
| Assets / Equity (Leverage) | 1.50 | |
| Net Debt / EBITDA | -0.89 | |
| Effective Interest Rate | 28.01% | |
| Debt / Revenue | 0.01 | |
| Efficiency (Computed) | ||
| Fixed Asset Turnover | 5.05 | |
| Receivables Turnover | 18.50 | |
| Dividends (Computed) | ||
| Payout Ratio | 0.49% | |
| Dividend Coverage | 12.28 | |
| Share Buyback Ratio | 0.00 | |
| Per Employee | ||
| Revenue / Employee | 54.64M | |
| Net Income / Employee | 5.77M | |
| Oper. Income / Employee | 9.15M | |
| Total Assets / Employee | 34.42M | |
| Balance Sheet (Computed) | ||
| Tangible Assets | 47.50B | |
| Invested Capital | 31.96B | |
| Working Capital | 17.62B | |
| Book Value Per Share | 323.04 | |
| Earnings Schedule | ||
| Next Earnings Date | 25 Feb 2027 | |
| Next Fiscal Period | 2026 | |